CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.

The primary goal when devising strategies to define the start of therapy in HIV infected individuals is to avoid HIV disease progression and toxicity from antiretroviral therapy (ART). Intermediate goals includes, avoiding resistance by suppressing HIV replication, reducing transmission, limiting spread and diversity of HIV within the body and protecting the immune system from harm. The question of how early or late to start ART and achieve both primary and intermediate goals has dominated HIV research. The distinction between early and late treatment of HIV infection is currently a matter of CD4+ T cells count, a marker of immune status, rather than on viral load, a marker of virus replication. Discussions about respective benefits of early or delayed therapy, as well as the best CD4+ T cell threshold during the course of HIV infection at which ART is initiated remains inconclusive. Guidelines issued by various agencies, provide different initiation recommendations. This can be confusing for clinicians and policy-makers when determining the best time to initiate therapy. Optimizing ART initiation strategies are clearly complex and must be balanced between individual and broader public health needs. This review assesses available data that contributes to the debate on optimal time to initiate therapy in HIV-infected asymptomatic individuals. We also review reports on CD4+ T cell threshold to guide initiation of ART and finally discuss arguments for and against early or late initiation of ART.

Low level of transmitted HIV Drug resistance at two HIV care centres in Ghana: a threshold survey.

BACKGROUND: As access to antiretroviral therapy (ART) increases, the emergence and transmission of HIV drug resistant strains becomes a major problem. The World Health Organization (WHO) therefore recommends an initial minimum-resource method to signal when transmitted HIV drug resistance (HIVDR) requires action. OBJECTIVE: This survey sought to generate information on the presence of HIV drug-resistant strains in the locality where Ghana's ART for HIV was first introduced. METHODS: The Ghana HIVDR threshold survey (TS) was conducted and analyzed according to WHO strategy for surveillance of HIVDR in the Eastern Region of Ghana. Sixty (60) plasma specimens were collected from 2007 to 2009 by an unlinked anonymous method from HIV seropositive pregnant women, aged between 15 to24 years, who were with their first pregnancy and ART naive. Genotyping was done as follows; Ribonucleic acid (RNA) was extracted from the samples and the protease (PR) and reverse transcriptase (RT) genes amplified and sequenced. The sequences were then analyzed for HIV drug resistance mutations using Stanford University HIV Drug Resistance Database. RESULTS: Only two individuals were found with major HIVDR mutations: one each in the PR and RT genes. Thus the level of HIVDR in the study population in 2009 was classified as low (< 5%). CONCLUSION: As at February 2009, transmitted drug resistance was not a serious problem in the Eastern Region of Ghana. However, it is important to continue monitoring tHIVDR in order to understand the dynamics of the evolution of HIV drug resistance in the country.

Laboratory diagnosis of dual HIV-1/HIV-2 infection in Ghanaian patients.

OBJECTIVE: To determine the true prevalence of HIV dual infections in a previously characterised HIV seropositive patient group due to inconsistencies between different diagnostic methods. DESIGN: A cross-sectional study of an HIV seropositive group with different diagnostic methods. SETTING: Three hospitals in the Northern, Ashanti and Greater Accra Regions of Ghana. SUBJECTS: One hundred and forty five HIV infected patients/individuals sampled from June to September 2002. MAIN OUTCOME MEASURES: Using serological and molecular methods, the seropositive status of HIV-infected patients, previously determined by a preliminary screening process, was confirmed and discrepancies noted. The data was used to propose a more accurate laboratory diagnosis of HIV dual infections involving HIV-1 and HIV-2. RESULTA: HIV-1 infections were mostly accurately detected, but difficulties were encountered in diagnosing HIV-2 infections. To achieve a positive detection on confirmatory immunoblots, antibody concentration in some samples tested was enhanced by using larger volumes. In other cases, diagnosis of HIV infections by PCR, especially HIV-2, was possible only after increasing the DNA template or MgCl2 concentrations. Such samples would otherwise have been inaccurately scored for HIV infections. CONCLUSION: Based on the results of this study, we propose that the accurate diagnosis of HIV dual infections, especially HIV-2 component, must use an algorithm that involves PCR. Our results however underscore conclusions of a previous study that most dually seroreactive samples are predominantly HIV-1 infections with crossreactivity to HIV-2 antigens.